Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Solid Tumors 1Pancreatic Neoplasms 1Haematological Malignancies 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Interventional × MSC1992371A × Clear all
NCT00391521 2014-01-30

AS703569 Phase I in Patients With Solid Tumours

EMD Serono

Phase 1 Completed
104 enrolled
Other solid neoplasm

Solid Tumors

NCT01097512 2014-01-30

AS703569 and Gemcitabine Combination in Advanced Malignancies

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
66 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01080664 2013-10-22

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

EMD Serono

Phase 1 Terminated
124 enrolled

Haematological Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡